Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Mustang Bio Announces Closing of $4 Million Public Offering
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
Mustang Bio Announces Pricing of $4 Million Public Offering
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
Avenue Therapeutics Announces Reverse Stock Split
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.